Medicare Enrolled
Dr. Rami Owera, M.D.
Hematology & Oncology · Pensacola, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Owera from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Owera? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Owera
Dr. Rami Owera is a hematology & oncology in Pensacola, FL, with 19 years in practice. Based on federal Medicare data, Dr. Owera performed 168,215 Medicare services across 3,832 unique beneficiaries.
Between the years covered by Open Payments, Dr. Owera received a total of $112,610 from 55 pharmaceutical and/or device companies across 404 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Owera is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 3% volume in FL$ $112,610 industry payments
Medicare Practice Summary
Medicare Utilization ↗168,215
Medicare services
Top 3% in FL for hematology & oncology
3,832
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~8,853 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 26,600 | $43 | $131 |
| Darbepoetin injection (Aranesp) for anemia | 26,425 | $2 | $21 |
| Filgrastim injection (Nivestym) for white blood cells | 22,020 | $0 | $2 |
| Azacitidine chemotherapy injection | 12,600 | $0 | $14 |
| Contrast dye for imaging (iodine-based) | 11,525 | $0 | $3 |
| Paclitaxel chemotherapy injection | 10,431 | $0 | $1 |
| Oxaliplatin chemotherapy injection | 9,470 | $0 | $36 |
| Anti-nausea injection (fosaprepitant) | 8,700 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 7,800 | $18 | $46 |
| Anti-nausea injection (aprepitant) | 7,280 | $1 | $8 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 5,230 | $24 | $166 |
| Immune globulin infusion (Octagam) | 2,530 | $34 | $231 |
| Iron infusion (Monoferric) | 2,200 | $16 | $71 |
| Dexamethasone injection (steroid) | 2,110 | $0 | $1 |
| Office visit, established patient (30-39 min) | 1,946 | $94 | $224 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,430 | $1 | $122 |
| Injection, granisetron hydrochloride, 100 mcg | 1,350 | $0 | $25 |
| Epoetin alfa injection (Retacrit) for anemia | 1,310 | $6 | $30 |
| Injection of additional new drug or substance into vein | 702 | $12 | $105 |
| Injection, leucovorin calcium, per 50 mg | 594 | $3 | $27 |
| Administration of chemotherapy into vein, 1 hour or less | 557 | $99 | $686 |
| Injection, gadobenate dimeglumine (multihance), per ml | 420 | $1 | $16 |
| Injection, carboplatin, 50 mg | 395 | $2 | $300 |
| Injection, fluorouracil, 500 mg | 394 | $2 | $12 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 360 | $81 | $157 |
| Drug injection, under skin or into muscle | 357 | $11 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 218 | $22 | $152 |
| Office visit, established patient (20-29 min) | 217 | $63 | $148 |
| Injection, zoledronic acid, 1 mg | 203 | $7 | $462 |
| Injection, magnesium sulfate, per 500 mg | 192 | $1 | $6 |
| Injection, diphenhydramine hcl, up to 50 mg | 173 | $1 | $5 |
| Office visit, established patient, complex (40-54 min) | 156 | $140 | $301 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 151 | $410 | $638 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 148 | $1,203 | $4,120 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 143 | $55 | $205 |
| Administration of additional new drug or substance into vein, 1 hour or less | 140 | $50 | $334 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 135 | $47 | $304 |
| Administration of chemotherapy into vein, each additional hour | 130 | $21 | $156 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 112 | $25 | $141 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 109 | $15 | $97 |
| CT scan of abdomen and pelvis with contrast | 103 | $223 | $1,400 |
| Ct scan of chest with contrast | 98 | $88 | $1,005 |
| New patient office visit (45-59 min) | 98 | $125 | $343 |
| Blood creatinine level | 91 | $5 | $30 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 83 | $40 | $226 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 65 | $4 | $26 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 60 | $1 | $19 |
| Diagnostic mammography of both breasts | 51 | $111 | $536 |
| Hospital follow-up visit, moderate complexity | 48 | $64 | $157 |
| CT scan of chest, without contrast | 45 | $92 | $861 |
| New patient office visit, complex (60-74 min) | 43 | $160 | $432 |
| Administration of additional new drug or substance into vein using push technique | 38 | $43 | $281 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 37 | $15 | $91 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 36 | $133 | $986 |
| Diagnostic mammography of 1 breast | 34 | $85 | $423 |
| Infusion into a vein for hydration, 31-60 minutes | 34 | $25 | $249 |
| Infusion, normal saline solution , 1000 cc | 30 | $2 | $19 |
| Screening mammography | 29 | $125 | $433 |
| 3D screening mammography (tomosynthesis) | 26 | $52 | $226 |
| Irrigation of implanted venous access drug delivery device | 23 | $15 | $111 |
| Initial hospital admission, moderate complexity | 23 | $106 | $297 |
| Mri scan of abdomen before and after contrast | 19 | $276 | $3,458 |
| Bone density scan (DEXA) | 19 | $37 | $421 |
| Mri scan of brain before and after contrast | 18 | $251 | $3,387 |
| Collection of blood sample from implanted device | 17 | $21 | $64 |
| Injection of drug or substance into vein | 17 | $29 | $240 |
| Ct scan of abdomen and pelvis without contrast | 16 | $149 | $892 |
| Complete ultrasound scan of 1 breast | 15 | $103 | $432 |
| Limited ultrasound scan of 1 breast | 13 | $71 | $355 |
| Initial hospital admission, high complexity | 12 | $140 | $412 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 11 | $41 | $166 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.2% high complexity
94.9% medium
1.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$112,610
Total received (2018-2024)
Avg $16,087/year across 7 years
Top 9% in FL for hematology & oncology
55
Companies
404
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$82,499 (73.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$26,214 (23.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,897 (3.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$16,459
2023$24,457
2022$11,995
2021$2,637
2020$9,624
2019$27,190
2018$20,248
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
BeiGene USA, Inc.
$30,788
Exelixis Inc.
$24,088
Janssen Biotech, Inc.
$15,003
Pharmacyclics LLC, An AbbVie Company
$9,541
Gilead Sciences, Inc.
$7,910
AstraZeneca Pharmaceuticals LP
$6,568
Kite Pharma, Inc.
$6,285
Ipsen Biopharmaceuticals, Inc
$4,707
Karyopharm Therapeutics Inc.
$1,550
E.R. Squibb & Sons, L.L.C.
$932
Adaptive Biotechnologies Corporation
$855
Novartis Pharmaceuticals Corporation
$852
Astellas Pharma US Inc
$648
BeiGene, Ltd.
$450
Celgene Corporation
$231
PFIZER INC.
$208
Eisai Inc.
$162
Amgen Inc.
$151
Genentech USA, Inc.
$149
GENZYME CORPORATION
$145
Merck Sharp & Dohme LLC
$124
Merck Sharp & Dohme Corporation
$116
Janssen Scientific Affairs, LLC
$111
Lilly USA, LLC
$95
Regeneron Healthcare Solutions, Inc.
$91
Mirati Therapeutics, Inc.
$78
ABBVIE INC.
$74
Takeda Pharmaceuticals U.S.A., Inc.
$65
EISAI INC.
$64
Sumitomo Pharma America, Inc.
$43
AVEO Pharmaceuticals, Inc.
$42
Daiichi Sankyo Inc.
$39
Seagen Inc.
$39
Bayer Healthcare Pharmaceuticals Inc.
$38
CSL Behring
$26
EMD Serono, Inc.
$25
Pharmacosmos Therapeutics Inc.
$24
Stemline Therapeutics Inc.
$21
Tempus AI, Inc
$21
Blueprint Medicines Corporation
$20
Heron Therapeutics, Inc.
$19
Progenics Pharmaceuticals, Inc.
$19
Bayer HealthCare Pharmaceuticals Inc.
$19
Janssen Pharmaceuticals, Inc
$18
Myovant Sciences Inc.
$17
Genmab U.S., Inc.
$17
Lexicon Pharmaceuticals, Inc.
$16
Incyte Corporation
$16
Novocure Inc.
$15
SpringWorks Therapeutics, Inc.
$13
Boehringer Ingelheim Pharmaceuticals, Inc.
$13
Coherus Biosciences Inc.
$13
GlaxoSmithKline, LLC.
$12
Teva Pharmaceuticals USA, Inc.
$12
Epizyme, Inc.,
$12
Top 3 companies account for 62.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AYVAKIT · Afstyla · Alecensa · BENDEKA · BLENREP · BOSULIF · BRUKINSA · Balversa · CABLIVI · CABOMETYX · CALQUENCE · CINVANTI · Cabometyx · DARZALEX · DAURISMO · ELITEK · ENHERTU · ERLEADA · Enhertu · Epkinly · Erleada · FOTIVDA · FRUZAQLA · Fabhalta · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONOFERRIC · MVASI · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · ONIVYDE · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Optune · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYLARIFY · Pomalyst · REBLOZYL · SARCLISA · SCEMBLIX · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · Tecartus · Tecentriq · Trodelvy · Udenyca · VENCLEXTA · VERZENIO · Venclexta · XARELTO · XPOVIO · XT CDX · XTANDI · Xermelo · Xtandi · Yescarta · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (73%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 9% for hematology & oncology in FL.
Equivalent to $67 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
20
Per 100K population
6.2
County median income
$65,715
Nearest hospital
BAPTIST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Owera is a mixed practice specialist, with above-average Medicare volume (top 3% in FL), and high industry engagement (speaking/promotional, top 9%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Owera experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Owera performed 26,600 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Owera receive payments from pharmaceutical companies?
Yes. Dr. Owera received a total of $112,610 from 55 companies across 404 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Owera's costs compare to other hematology & oncologys in Pensacola?
Dr. Owera's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Owera) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Pensacola
Browse hematology & oncologys in Pensacola ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc..
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology